Payment overview · 2025
General Payments
$595.29
29 reported records · 11 companies
Healthcare provider profile · identity verified
Donna Jenkins Pause, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MONROE, GA · NPI 1003282120
Verified facts
What the public records show
CMS Open Payments records show Donna Jenkins Pause, NP-C received $595.29 in general payments during 2025 across 29 reported records.
Medtronic, Inc. accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$191.83 | 32.2% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $120.93 | 20.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.07 | 14.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.88 | 6.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.42 | 6.3% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.90 | 4.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.30 | 4.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.24 | 3.4% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $17.36 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.51 | 2.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.85 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $595.29 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $191.83 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.93 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $86.07 | 5 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $86.07 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.88 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $25.90 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.89 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
102 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 245 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 233 | 81 |
| Gabapentin | Gabapentin | 200 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 75 |
| Losartan Potassium | Losartan Potassium | 165 | 54 |
| Metformin Hcl | Metformin Hcl | 164 | 56 |
| Omeprazole | Omeprazole | 153 | 55 |
| Lisinopril | Lisinopril | 130 | 44 |
| Alprazolam | Alprazolam | 128 | 29 |
| Famotidine | Famotidine | 116 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 115 | 35 |
| Ozempic | Semaglutide | 114 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 39 |
| Sertraline Hcl | Sertraline Hcl | 109 | 34 |
| Tramadol Hcl | Tramadol Hcl | 109 | 37 |
| Furosemide | Furosemide | 106 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 35 |
| Mounjaro | Tirzepatide | 102 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 100 | 29 |
| Prednisone | Prednisone | 100 | 78 |
| Trazodone Hcl | Trazodone Hcl | 97 | 33 |
| Carvedilol | Carvedilol | 92 | 32 |
| Potassium Chloride | Potassium Chloride | 89 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 88 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 24 |
| Glipizide Er | Glipizide | 73 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 23 |
| Simvastatin | Simvastatin | 69 | 25 |
| Azithromycin | Azithromycin | 66 | 61 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 29 |
| Cephalexin | Cephalexin | 65 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 49 |
| Metformin Hcl Er | Metformin Hcl | 58 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 44 |
| Eliquis | Apixaban | 53 | 15 |
| Meloxicam | Meloxicam | 52 | 24 |
| Montelukast Sodium | Montelukast Sodium | 50 | 16 |
| Aripiprazole | Aripiprazole | 49 | 18 |
| Amoxicillin | Amoxicillin | 48 | 31 |
| Celecoxib | Celecoxib | 48 | 14 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Glipizide | Glipizide | 47 | 23 |
| Jardiance | Empagliflozin | 47 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 17 |
| Ezetimibe | Ezetimibe | 45 | 16 |
| Alendronate Sodium | Alendronate Sodium | 44 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 14 |
| Ibuprofen | Ibuprofen | 42 | 16 |
| Pregabalin | Pregabalin | 41 | 18 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 14 |
| Promethazine Hcl | Promethazine Hcl | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 19 |
| Linzess | Linaclotide | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | 11 |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Torsemide | Torsemide | 28 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 14 |
| Ondansetron Odt | Ondansetron | 26 | 11 |
| Valacyclovir | Valacyclovir Hcl | 26 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 23 |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Nystatin | Nystatin | 17 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 12 |
| Lorazepam | Lorazepam | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 11 |
| Valsartan | Valsartan | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Promethegan | Promethazine Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $595.29 · 29 records | Medtronic, Inc. | AIRSUPRA, EVENITY, JARDIANCE, KISUNLA, Kerendia, MINIMED 780G, NEXLETOL, PROLIA, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Vest Therapy Und | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error